A transplant drug plan meant to keep lymphoma out of the brain and spine
Original title: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so we do not know yet if it works.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a transplant drug plan meant to keep lymphoma out of the brain.
Who this trial is for. This trial is for people with a blood cancer called diffuse large B cell lymphoma. They must be in their first full remission and well enough for a stem cell transplant. They must never have had this cancer in the brain or spine, but be at high risk of it going there. The trial tests two drugs, thiotepa and carmustine, given before the transplant.
Where it stands. This trial has not reported results. It is measuring whether this drug plan lowers the chance the lymphoma comes back in the brain or spine. That answer is not in yet.
What this means, and what it doesn't
What it could mean: About 5% of people with this lymphoma have it come back in the brain or spine. This trial is testing one way to try to lower that risk. If this sounds like your situation, you can ask your care team about it.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one is not a guarantee that you will be helped. This is not a promise of a cure. Right now, no one knows if this drug plan works better.
Source: ClinicalTrials.gov, August 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.